MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Early Phase 1
Completed
Conditions
Rhytides
Interventions
Drug: PrabotulinumtoxinA-Xvfs
First Posted Date
2023-04-11
Last Posted Date
2024-03-13
Lead Sponsor
Lupo Center for Aesthetic and General Dermatology
Target Recruit Count
10
Registration Number
NCT05807412
Locations
🇺🇸

Lupo Center for Aesthetic and General Dermatology, New Orleans, Louisiana, United States

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Phase 4
Recruiting
Conditions
Urgency Urinary Incontinence
Interventions
Drug: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
First Posted Date
2023-04-10
Last Posted Date
2025-03-28
Lead Sponsor
Women and Infants Hospital of Rhode Island
Target Recruit Count
432
Registration Number
NCT05806164
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of California, San Diego, San Diego, California, United States

and more 2 locations

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Phase 1
Active, not recruiting
Conditions
Glabellar Frown Lines
Interventions
First Posted Date
2023-03-13
Last Posted Date
2024-04-04
Lead Sponsor
Henry Ford Health System
Target Recruit Count
20
Registration Number
NCT05766683
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.

Not Applicable
Terminated
Conditions
Transfusion Dependent Beta-Thalassaemia
Interventions
First Posted Date
2023-03-02
Last Posted Date
2025-03-30
Lead Sponsor
EdiGene (GuangZhou) Inc.
Target Recruit Count
2
Registration Number
NCT05752123
Locations
🇨🇳

PLA 923 Hospital, Nanning, Guangxi, China

Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A

Phase 2
Recruiting
Conditions
Temporomandibular Disorders
Interventions
Drug: Isotonic saline 0,9%
First Posted Date
2023-02-09
Last Posted Date
2025-02-17
Lead Sponsor
Karolinska Institutet
Target Recruit Count
50
Registration Number
NCT05720065
Locations
🇸🇪

Department of Dental Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden

Efficacy of Botulinum Toxin in Temporomandibular Disorders

Phase 2
Completed
Conditions
Temporomandibular Joint Disorder Bilateral
Interventions
First Posted Date
2022-12-14
Last Posted Date
2022-12-14
Lead Sponsor
University of Salamanca
Target Recruit Count
20
Registration Number
NCT05651256
Locations
🇪🇸

Clinica Odontológica de la Universidad de Salamanca, Salamanca, Spain

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Phase 2
Recruiting
Conditions
Dry Eye Syndromes
Meige Syndrome
Blepharospasm
Hyperactivity
Interventions
First Posted Date
2022-11-16
Last Posted Date
2022-11-17
Lead Sponsor
China Academy of Chinese Medical Sciences
Target Recruit Count
80
Registration Number
NCT05618470
Locations
🇨🇳

Eye Hospital, China Academy of Chinese Medical Sciences;GuangAnmen Hospital, China Academy of Chinese Medical Sciences;XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China

BTA vs Baclofen for Pelvic Myofascial Pain Syndrome

Recruiting
Conditions
Chronic Pain
Chronic Pelvic Pain Syndrome
Myofascial Pain Syndrome
Myofascial Trigger Point Pain
Pelvic Floor Disorders
Interventions
First Posted Date
2022-11-15
Last Posted Date
2023-04-11
Lead Sponsor
Saint Petersburg State University, Russia
Target Recruit Count
52
Registration Number
NCT05617118
Locations
🇷🇺

SBPSU, Saint Petersburg, Russian Federation

Comparison of Botulinum Toxin Injection Techniques in Spasticity

Phase 4
Not yet recruiting
Conditions
Spastic Hemiplegia
Interventions
First Posted Date
2022-11-14
Last Posted Date
2022-11-14
Lead Sponsor
Konya Beyhekim Training and Research Hospital
Target Recruit Count
60
Registration Number
NCT05615987
Locations
🇹🇷

Konya Beyhekim Research and Training Hospital, Konya, Selçuklu, Turkey

BOTOX Effects on Seizure Severity and Susceptibility

Phase 4
Terminated
Conditions
Drug-resistant Focal Seizure
Interventions
First Posted Date
2022-11-04
Last Posted Date
2025-01-23
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
3
Registration Number
NCT05605756
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath